Swiss Cardio Technologies AG, established by renowned cardiovascular surgeons from the University of Berne, developed Cardioplexol®, an innovative cardioplegia solution used to safely arrest the heart during complex surgical procedures such as bypass operations and aortic repairs. The transaction is expected to accelerate international commercialization and expansion of Cardioplexol®, leveraging Abacus’ extensive global network alongside Swiss Cardio Technologies’ relationships in cardiothoracic surgery.
Baker McKenzie advised the shareholders of Swiss Cardio Technologies on all legal aspects of the transaction.
Zurich-based partners Alexander Fischer (M&A) and Julia Schieber (M&A, Healthcare & Sciences) led the team, which consisted of the following: Matthias Trautmann (partner, M&A), Hesam Mirzai (associate, M&A) as well as trainee lawyers Elena Mani and Grégory Sarbach.